Pharma Success in Product Development—Does Biotechnology Change the Paradigm in Product Development and Attrition
Journal Title: The AAPS Journal - Year 2016, Vol 18, Issue 1
Abstract
The biotechnology segment of the overall biopharma industry has existed for only about 40–45 years, as a driver of new product development. This driving force was initiated with the FDA approval of recombinant human insulin in 1982, originating from the Genentech company. The pharma industry in the early years of 1970s and 1980s engaged with biotechnology companies only to a small extent with their in-licensing of a few recombinant molecules, led by Roche, Eli Lilly, and Johnson and Johnson. However, subsequently and dramatically over the last 25 years, biotechnology has become a primary driver of product and technology innovation and has become a cornerstone in new product development by all biopharma companies. This review demonstrates these evolutionary changes regarding approved products, product pipelines, novelty of the products, FDA approval rates, product sales, financial R&D investments in biotechnology, partnerships, mergers and acquisitions, and patent issues. We now have about 300 biotechnology products approved in USA covering 16 medical disciplines and about 250 indications, with the engagement of 25 pharma companies, along with their biotechnology company innovators and partners. The biotechnology pipeline involves over 1000 molecules in clinical trials, including over 300 molecules associated with the top 10 pharma companies. Product approval rates by the FDA for biotechnology products are over double the rate for drugs. Yes, the R&D paradigm has changed with biotechnology now as one of the major focuses for new product development with novel molecules by the whole biopharma industry.
Authors and Affiliations
Ronald P. Evens
Keywords
Related Articles
- EP ID EP680837
- DOI 10.1208/s12248-015-9833-6
- Views 40
- Downloads 0
Liquid Chromatography-High Resolution Mass Spectrometry for Peptide Drug Quality Control
A liquid chromatography-high resolution mass spectrometry (LC-HRMS) method was developed using three peptide drugs: salmon calcitonin, bivalirudin, and exenatide as model systems to assess the suitability of this approac...
Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites
The online version of this article (doi:10.1208/s12248-012-9443-5) contains supplementary material, which is available to authorized users.
Comparative In Silico–In Vivo Evaluation of ASGP-R Ligands for Hepatic Targeting of Curcumin Gantrez Nanoparticles
The online version of this article (doi:10.1208/s12248-013-9474-6) contains supplementary material, which is available to authorized users.
Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches
The online version of this article (doi:10.1208/s12248-015-9745-5) contains supplementary material, which is available to authorized users.
Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans
To investigate the potential added value of intranasal drug administration, preclinical studies to date have typically used the area under the curve (AUC) in brain tissue or cerebrospinal fluid (CSF) compared to plasma f...